www.fdanews.com/articles/205136-who-considers-mercks-antiviral-covid-19-pill-for-mild-and-moderate-cases
WHO Considers Merck’s Antiviral COVID-19 Pill for Mild and Moderate Cases
November 2, 2021
The World Health Organization (WHO) wants Merck to provide additional data on its investigational COVID-19 antiviral, molnupiravir, co-developed with Ridgeback Biotherapeutics.
The WHO is considering releasing guidance in the coming weeks on administering the oral medication for mild and moderate COVID-19 infections.
In the U.S., an FDA advisory committee is set to consider molnupiravir on Nov. 30 and offer its recommendation on whether the drug should be authorized for emergency use.